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nKG2D: A Master Regulator of 
immune Cell Responsiveness
Felix M. Wensveen, Vedrana Jelencˇić and Bojan Polić*
Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
NKG2D is an activating receptor that is mostly expressed on cells of the cytotoxic arm 
of the immune system. Ligands of NKG2D are normally of low abundance, but can 
be induced in virtually any cell in response to stressors, such as infection and onco-
genic transformation. Engagement of NKG2D stimulates the production of cytokines 
and cytotoxic molecules and traditionally this receptor is, therefore, viewed as a mol-
ecule that mediates direct responses against cellular threats. However, accumulating 
evidence indicates that this classical view is too narrow. During NK cell development, 
engagement of NKG2D has a long-term impact on the expression of NK cell receptors 
and their responsiveness to extracellular cues, suggesting a role in NK cell education. 
Upon chronic NKG2D engagement, both NK and T cells show reduced responsiveness 
of a number of activating receptors, demonstrating a role of NKG2D in induction of 
peripheral tolerance. The image that emerges is that NKG2D can mediate both inhibitory 
and activating signals, which depends on the intensity and duration of ligand engage-
ment. In this review, we provide an overview of the impact of NKG2D stimulation during 
hematopoietic development and during acute and chronic stimulation in the periphery 
on responsiveness of other receptors than NKG2D. We propose that NKG2D interprets 
the context of the immunological environment through detection of cellular cues and 
in response sets the appropriate activation threshold for a large number of immune 
receptors. This perspective is of particular importance for future therapies that aim to 
exploit NKG2D signaling to fight tumors or infection.
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inTRODUCTiOn
NKG2D, encoded by Klrk1, is an activating cell surface receptor that is predominantly expressed on 
cytotoxic immune cells. NKG2D is abundantly present on all NK cells, NKT cells, and subsets of 
γδ T cells. While naïve human CD8+ T cells express NKG2D, in mice they upregulate its expression 
only after activation (1). CD4+ T cells generally do not express NKG2D even after activation, but in 
humans its expression can be induced under certain pathological conditions, such as Crohn’s disease 
juvenile-onset lupus and cytomegalovirus infection (2–4). In mice, CD4 T cells were shown to induce 
NKG2D expression in models for inflammation, such as colitis and chronic inflammatory arthritis 
(5, 6). The molecular structure of NKG2D allows it to bind a number of structurally different MHC-
I-like ligands. NKG2D ligands have in common that under homeostatic conditions their expression 
is generally low. In contrast, upon cellular stress, such as infection or oncogenic transformation, 
their expression can be highly induced (7). In humans, the NKG2D ligands are MICA, MICB, and 
six members of the ULBP family. In mice, ligands can be divided into three subgroups: five different 
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isoforms of the Rae1-family (α-ε), MULT1, and three different 
isoforms of H60 (a, b, and c) (7).
The NKG2D receptor consists of a homodimer of two disulfide-
linked transmembrane proteins, with very short intracellular 
domains that do not have signaling properties. In mice, NKG2D 
therefore uses the adaptor molecules DAP10 and DAP12 to relay its 
signaling, whereas in humans NKG2D associates exclusively with 
DAP10 (8). Two NKG2D isoforms have been identified in mice, 
a short (NKG2D-S) and a long (NKG2D-L) form, which differ 
13 amino acids in length as result of alternative splicing of the 
Klrk1 transcript (9). Due to this difference in length, NKG2D-L 
can only associate with DAP10, whereas NKG2D-S can form 
a complex with both DAP10 and DAP12. In humans, only the 
NKG2D-L isoform is expressed explaining why this receptor 
exclusively signals through DAP10 (10, 11). DAP10 and DAP12 
initiate different signaling cascades. DAP10 possesses a YINM 
motif which allows binding p85 of phosphatidylinositol-3 kinase 
(PI3K) (12). In addition, DAP10 binds Grb2, which associates 
with Vav1. All three of these molecules are required to mediate 
the full signaling potential of NKG2D over DAP10 (13). DAP12 
contains an immune receptor tyrosine-based activation motif, 
which is phosphorylated by Src-kinases upon NKG2D triggering 
(14). This event allows binding and activation of the tyrosine 
kinases, Syk and Zap70 (12). T cells and naïve NK cells predomi-
nantly express the NKG2D-L isoform, which is therefore thought 
to promote cellular processes downstream of the PI3K signaling 
cascade, such as co-stimulation, cytotoxicity, and cell survival 
(15–17). In mice, NKG2D-S is induced in activated NK  cells, 
in which it promotes signaling through Syk/Zap70, resulting in 
enhanced cytotoxicity and cytokine production (17).
NKG2D plays an important role in the recognition and elimi-
nation of potentially dangerous cells (1, 18). It has been shown to 
mediate immune responses against tumors (18), virally infected 
cells (8, 19), and organ transplants (20). For this reason, NKG2D 
was originally thought to predominantly mediate direct cyto-
toxicity in response to the encounter of ligand on stressed target 
cells (1). However, in most cases, NKG2D is only able to medi-
ate immune cell activation if it occurs within an inflammatory 
context. Both NK and T cells generally require a secondary signal 
before NKG2D is able to mediate a measurable effect (21–23). The 
primary function of NKG2D therefore appears to be regulation of 
signaling through other receptors. Its unique feature is that it is 
able to both inhibit and potentiate signaling of a large number of 
receptors in multiple ontologically distinct immune cell subsets 
and during different stages of the life cycle of immune cells, such 
as hematopoietic development, priming, and effector responses 
(8). In this review, we will give a brief overview of the literature 
regarding the role of NKG2D in various immunological settings. 
The model that emerges from accumulated evidence is that 
NKG2D is a master regulator of activation thresholds for a large 
number of receptors, both when NKG2D is directly engaged, and 
long after its signaling has ceased.
nKG2D AnD nK CeLLS
As part of innate immunity, NK cells play an important role in 
the early cytolytic defense against infections and tumors. NK cells 
are members of the type 1 family of innate lymphoid cells (24, 25). 
On their cell surface they express a large number of structurally 
distinct, germline-encoded receptors that can transfer both 
activating and inhibitory signals into the cell (26). These recep-
tors respond to external cues from peripheral cells that com-
municate either inhibitory homeostatic signals, or activating 
signals in case of cellular stress (7). Under normal conditions 
inhibitory signals prevail, which keeps NK cells inactive. When 
cells become stressed, for example, upon infection or oncogenic 
transformation, activating signals dominate causing loss of equi-
librium and NK  cell activation (27). To prevent autoimmunity 
or anergy, an extensive set of regulatory mechanisms is in place 
that determines the activation threshold values beyond which the 
balance between inhibitory and stimulating cues shifts in favor of 
activation. Already during their development, in a process known 
as “education,” “licensing,” or “arming,” NK cell activation thresh-
olds are set, mostly in response to inhibitory receptors. NK cell 
education ensures proper reactivity, as well as tolerance toward 
self in response to locally expressed ligands. This process func-
tionally mimics positive and negative selection of T cells in the 
thymus (28–30). Outside of the bone marrow, the responsiveness 
of NK cells is further fine-tuned by engagement of self-ligands by 
their receptor array, which mediates peripheral tolerance.
NKG2D is expressed from the earliest NK  cell precursor 
stages onward (31). Initially, its expression is relatively low, but 
increases over time and stays high in mature cells (32). In mice, 
NK cells express both NKG2D isoforms, even though the long form 
predominates in a resting state (9). Expression of the NKG2D-S 
isoform strongly increases after NK  cell activation, whereas 
levels of the L-form abate (10). Nevertheless, both DAP10 and 
DAP12-mediated signaling is engaged upon NKG2D stimulation 
in activated murine NK cells (15). NKG2D has been implied in 
NK cell education, effector cell function, and peripheral tolerance 
through modification of the activation threshold of NK cell recep-
tors. During development, NKG2D regulates both expression 
levels and responsiveness of a plethora of receptors (Figure 1). 
NK  cells of mice with a germline deficiency for NKG2D show 
reduced levels of c-kit (CD117), the activating receptor DNAM-
1, as well as the inhibitory receptors Ly49A, Ly49G2, and Ly49F 
(33, 34). In addition, whereas Klrk1−/− NK cells fail to respond 
to target cells expressing NKG2D ligands (33, 35), mice lacking 
either NKG2D, or its ligands Rae1δ and Rae1ε produce higher 
levels of IFNγ following stimulation with cellular targets (33, 34, 
36). As a result, NKG2D-deficient mice display better NK cell-
mediated control of murine cytomegalovirus infection (33). 
This effect seems specific for NKG2D, since deletion of CD16, 
another activating receptor expressed on all NK cells, does not 
affect CD16 independent NK cell function both in humans and 
in mice (37–39).
Humans do not express Ly49 molecules, nor does human 
NKG2D engage DAP12. Unfortunately, the impact of NKG2D 
on NK cell development in humans is difficult to determine. To 
date, no deficiency for this receptor has been documented and in 
the periphery most NK cells express NKG2D, precluding com-
parison of NK cell subpopulations with and without this receptor. 
This makes it difficult to translate many observations made in 
NKG2D-deficient mice directly to the human situation. However, 
FiGURe 1 | NKG2D mediates education of NK cells. NKG2D signaling during development negatively affects responsiveness of NK cells in two ways. On one hand, 
it promotes expression of inhibitory Ly49 molecules, such as Ly49F, G2, or A, whereas it inhibits expression of activating receptors, such as DNAM-1. On the other, 
it reduces responsiveness of activating receptors, such as NKp46 and Ly49D. As a consequence, mice deficient for NKG2D have a hyper-responsive phenotype 
and are better protected against infection with pathogens which are controlled by NK cells, such as cytomegalovirus (33, 34).
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the maternal decidua contains a large population of NKG2D− 
NK cells, which is replaced by NKG2D+ cells during the first tri-
mester of pregnancy (40). Notably, this is associated with strong 
changes in the KIR repertoire and reduced pro-inflammatory 
NK cell function (40, 41). These observations suggest that also in 
humans NKG2D may affect NK cell development and education.
The impact of NKG2D on NK  cell development is likely to 
depend on its interaction with the IL-15 receptor (IL-15R). 
IL-15R signaling is known to be important for the development, 
homeostasis, and survival of NK cells (42). Both NKG2D and the 
IL-15R were shown to be able to bind DAP10 in murine cells (16). 
Jak3, as part of the canonical IL-15R signaling pathway, phospho-
rylates the YINM sequence on DAP10 and was shown to be able 
to potentiate NKG2D signaling (16). Klrk1−/− mice show a higher 
proliferation rate as well as faster differentiation and transition to 
more mature stages resulting in perturbation in size of immature 
NK  cell subpopulations (33). Importantly, NKG2D-deficient 
NK cells are prone to apoptosis, which could not be corrected by 
addition of IL-15 (33), suggesting a common signaling pathway. 
Both NKG2D and the IL-15R can activate PI3 kinase, a molecule 
important for the regulation of proliferation and survival (43). 
It therefore seems likely that the PI3K pathway is engaged by 
these receptors to mediate common regulatory effects. Whether 
NKG2D prevents a general hyper-reactivity of NK cells or if it 
sets the activation threshold of a specific activating NK cell recep-
tor still needs to be investigated.
NKG2D plays a key role in effector responses of NK cells in the 
periphery (Figure 2). NKG2D itself is an important mediator of 
tumor immuno-surveillance, since animals deficient for NKG2D 
demonstrate a reduced ability to fight prostate carcinoma and 
B  cell lymphoma, but not chemically induced fibrosarcoma 
(35). In addition, NKG2D ligation was shown to reduce activa-
tion thresholds for several NK receptors, both in humans and 
in mice. In human NK cells, NKG2D promotes CD16 signaling 
and ADCC, since blocking of NKG2D receptors results in a 
reduced ability of NK  cells to mediate anti-HIV-1 antibody-
dependent cellular cytotoxicity (44). Conversely, NKG2D was 
shown to be able to synergistically activate human NK cells when 
they were simultaneously stimulated through CD16, NKp46, or 
2B4 (23, 45). For the 2B4-NKG2D pair, it was shown that syn- 
ergy is achieved through conversion on the signaling adaptor 
Vav1, which overcomes c-Cbl-mediated inhibition (46). In mice, 
NKG2D was shown to augment Ly49H-dependent proliferation 
(47). Wild type Ly49H+ NK  cells proliferate faster than their 
Klrk1−/− counterparts following infection with a virus that drives 
overexpression of the NKG2D ligand Rae1γ (47). Both NKG2D 
and Ly49H use DAP12 for their signal transduction providing 
a possible overlap in signaling cascades. It should be noted, 
however, that the Rae1γ transgenic virus mediates important 
NKG2D-independent effects (48) and additional evidence is 
required before NKG2D and Ly49H signaling can be directly 
linked.
NKG2D has also been implied in the generation of peripheral 
tolerance of NK cells, an effect that was first identified in cancer 
patients. Whereas some tumors downregulate NKG2D ligands 
to prevent recognition, others paradoxically induce expression 
NKG2D ligands (49). Rather than activating NK  cells, high 
NKG2D ligand expression mediates downregulation of the 
NKG2D receptor on tumor infiltrating lymphocytes (TILs) and 
reduced responsiveness to NKG2D engagement (50). Under 
physiological conditions, this process is thought to prevent NK 
hyper-responsiveness against peripheral ligands for which edu-
cation in the bone marrow is incomplete. In addition, it allows 
induction of NK cell hypo-responsiveness at times when this is 
required, for example during pregnancy (41). The human placenta 
was shown to produce both soluble and exosome-bound NKG2D 
ligands. During pregnancy, the placenta accumulates a large 
number of NK  cells, which are inhibited from recognizing the 
fetus as non-self. Both supernatants of umbilical cord cells and 
placental exosomes were shown to downmodulate NKG2D and 
inhibit NK cell cytotoxicity (51–53). Loss of NK cell functional-
ity after exosome treatment could be prevented using blocking 
antibodies directed against NKG2D. NKG2D-induced hypo-
responsiveness was therefore proposed as a mechanism to medi-
ate fetal tolerance. Indeed, several polymorphisms in NKG2D 
and MICA are associated with recurrent miscarriage (54).
FiGURe 2 | NKG2D regulates receptor responsiveness differently following acute or chronic stimulation. (A) Following acute stimulation, NKG2D promotes 
responsiveness of a range of structurally unrelated receptors that use largely distinct intracellular signaling modalities. (B) Chronic NKG2D engagement mediates its 
own downregulation and subsequent hypo-responsiveness to stimulation. In addition, chronic NKG2D stimulation impairs T cell receptor responsiveness in T cells. 
In NK cells, chronic NKG2D stimulation reduces missing self-signaling (not shown) as well as responsiveness of a number of receptors that share the FcεRIγ signal 
adaptor.
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Chronic NKG2D engagement by NK cells results in reduced 
responsiveness of multiple receptors other than NKG2D. An 
impaired ability to kill RMA-S cells was observed in mice that 
transgenically overexpress Rae1ε or MICA and upon chronic 
exposure of NK cells to NKG2D ligands in vitro. This indicates 
a role for NKG2D in regulation of missing self-recognition 
(55–57). When murine NK cells were long-term exposed to cells 
overexpressing the NKG2D ligand H60, they showed reduced 
responsiveness to CD16, NK1.1, and NKp46 stimulation (55). 
NKG2D-induced peripheral tolerance demonstrated receptor 
specificity, since Ly49H and Ly49D function were reduced, but 
still partially preserved (55). Similarly, when human NK  cells 
were chronically exposed to MICA, downregulation of CD3ζ was 
observed, rendering them hypo-responsive to CD16, NKp46, 
and NKp30, but not 2B4 stimulation (58). In mice, NK  cell 
hypo-responsiveness following chronic NKG2D engagement 
requires signaling through both DAP10 and DAP12 adaptor 
molecules (55). Interestingly, most receptors affected by chronic 
NKG2D exposure, such as NK1.1, NKp46, or CD16, do not make 
complexes with either DAP10 or DAP12, but rather use the adap-
tor molecule FcεRIγ (59). This implies that prolonged NKG2D 
stimulation influences signaling components downstream of 
FcεRIγ. Again, it seems that this level of regulation is specific for 
NKG2D since sustained exposure of murine NK cells to CD16, 
another broadly expressed NK cell activating receptor, did not 
affect any other activation pathway besides CD16-mediated 
NK cell activation (55). NKG2D-mediated peripheral tolerance 
appears to depend on the level of stimulation. Chronic exposure 
of murine NK cells to Rae1ε or Rae1δ, NKG2D ligands of relatively 
low affinity, induced general hypo-responsiveness of NK cells to 
activating stimuli (“desensitization”). Tolerance could be broken 
through administration of soluble MULT1, an NKG2D ligand 
that binds this receptor with high affinity (36). How this effect 
is mediated molecularly, or why a difference in the affinity of 
NKG2D ligands has such opposing effects on NK cell activity is 
still unknown.
In summary, NKG2D affects all stages of the life cycle of 
NK  cells through modification of NK  cell receptor activation 
thresholds. In addition to its important role in recognition and 
elimination of potentially dangerous cells, NKG2D mediates 
NK cell education in the bone marrow and peripheral tolerance 
upon chronic ligand exposure. Further investigation is needed to 
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determine how NKG2D affects activity of receptors that do not 
share its downstream signaling components.
nKG2D AS A MODULATOR OF ReCePTOR 
ReSPOnSiveneSS in T CeLLS
Inappropriate activation of T cells, for example by self antigens, 
may lead to devastating tissue destruction. Therefore, priming of 
naïve T cells requires not only T cell receptor (TCR) engagement, 
but also co-stimulation via membrane-bound receptors and/
or cytokines (60). Co-stimulatory molecules ensure survival of 
T cells and control responsiveness of TCR engagement of effector 
cells in the periphery. The most well-documented co-stimulatory 
molecule is CD28. Upon engagement of B7 molecules, this pro-
tein activates several signaling cascades, including the NF-kB and 
PI3 kinase pathways (61). Deficiency of CD28 causes a reduction 
in proliferation and cytokine production by T cells upon infection 
(61). T cells expressing a mutant form of CD28 that lacks the PI3K 
binding YMNM motif have a specific impairment in producing 
cytokines (62). This indicates that co-stimulatory functions are 
associated with specific signaling cascades. Indeed, deficiency of 
CD28 does not abrogate the cytotoxic response against LCMV 
infection (63), demonstrating that co-stimulation does not neces-
sarily induce a general state of increased responsiveness, but is 
able to potentiate specific receptors.
NKG2D has been well-documented as a co-stimulatory 
molecule for T cells. Upon MICA engagement, activated human 
CD8 T  cells produce more IFNγ, TNF, and IL-2 in response 
to TCR stimulation (22). Moreover, the cytolytic response of 
antigen-specific CD8 T cells against peptide-pulsed target cells is 
enhanced if these cells overexpress ligands for NKG2D (22, 64). 
For priming of naïve CD8 T  cells, NKG2D is insufficient as a 
co-stimulatory molecule. In vitro stimulation of human peripheral 
blood CD8 T cells showed that CD28-mediated co-stimulation is 
required for NKG2D to be able to promote cytokine production 
and cytotoxicity following TCR stimulation (65). The in vivo role 
of NKG2D on T  cells long remained elusive, because NKG2D 
deficiency on NK cells results in their hyper-responsiveness, thus 
affecting viral titers and the subsequent CD8 T  cell responses 
(33, 66). Specific elimination of NKG2D on CD8 T cells demon-
strated that this receptor has a non-redundant role in promoting 
cytokine production following viral infection in mice (66).In 
contrast, deficiency of NKG2D on these cells did not impact their 
ability to expand or mediate cytotoxicity (66). Conversely, when 
mice are infected with a cytomegalovirus strain that transgeni-
cally expresses the NKG2D ligand Rae1γ, no major differences 
in effector CD8 T cell numbers are observed, but these cells do 
display increased cytokine production and cytotoxic potential 
(48). This indicates that NKG2D is able to promote cytotoxicity 
in antiviral CD8 T cells, but is not required by these cells to obtain 
their normal cytolytic potential.
In contrast to αβ T  cells, γδ T  cells do not require priming 
and are directly able to mediate cytokine production and cytol-
ytic killing upon TCR engagement (67). γδ T cells constitutively 
express NKG2D. However, most γδ T cells are not able to mediate 
cytotoxicity upon NKG2D triggering alone (68, 69). Indeed, also 
in γδ T cells does NKG2D function to potentiate TCR responsive-
ness with regards to cytokine production and target cell lysis (68, 
70).
The TCR functionally defines the T  cell and, therefore, has 
been given most attention regarding its interaction with NKG2D. 
However, NKG2D mediates sensitization of receptors in T cells 
beyond the TCR (Figure  2). Most notably, NKG2D has been 
associated with IL-15 receptor signaling and memory CD8 T cell 
formation. Upon stimulation, the IL-15 receptor activates the 
adaptor molecules Jak1 and Jak3, which mediate phosphorylation 
of Stat5, but also DAP10, thus potentiating NKG2D signaling 
through DAP10 (16). Indeed, both DAP10 expression and IL-15 
stimulation mediate NKG2D expression on the surface of murine 
effector CD8 T  cells (15, 71). Conversely, NKG2D potentiates 
IL-15R signaling in memory CD8 T cell precursors. Upon LCMV 
infection, murine CD8 T cells deficient for NKG2D have a reduced 
capacity to form central memory cells, which is DAP10 and IL-15 
dependent (72). In absence of NKG2D, memory precursor CD8 
T  cells show reduced phosphorylation of Akt, a downstream 
target of PI3 kinase, following IL-15 stimulation. As a result, these 
cells have a reduced ability to sustain levels of the pro-survival 
protein Mcl-1, leading to lower number of central memory cells 
(72). Thus, both in NK and CD8 T cells, NKG2D and the IL-15R 
potentiate each other’s signaling through DAP10 even though 
the functional outcome differs between these cell subsets. In 
murine memory T cell precursors, NKG2D also mediates down-
regulation of the transcription factor T-bet by limiting JNK2 
signaling (73). Whether this effect is downstream of the IL-15R 
or of another ligand was not shown (73).
FAS, also known as CD95, is a member of the TNF receptor 
superfamily. Dependent on the intracellular adaptor molecules 
that are associated to this receptor, FAS ligation may induce 
apoptosis, growth arrest, or proliferation (74). In a large number 
of human tumors, infiltrating CD4 T cells were shown to express 
high levels of NKG2D (75). Rather than inducing a cytolytic 
response, MICA expression by these tumors induced expression 
of FASL by NKG2D-expressing CD4 T cells. Whereas, tumor cells 
themselves were protected against FASL-induced apoptosis, it 
did mediate growth arrest in NKG2D−, but not in NKG2D+ cells 
(75). In glioblastoma cells, FAS was shown to recruit the p85 
subunit of PI3 kinase, which enhanced invasive growth (76). 
Since NKG2D/DAP10 signals through PI3K in T cells, it seems 
likely that this mechanism is adopted in tumor infiltrating T cells 
to prevent FASL-mediated growth arrest.
Finally, NKG2D stimulation affects responsiveness of T cells to 
chemokines. Deficiency of NKG2D does not result in changes in 
migration per se, as naïve or effector T cells of NKG2D-deficient 
mice do not show differences in tissue homing (66). However, 
in a mouse that transgenically overexpressed the NKG2D ligand 
Rae1ε in pancreatic β-islet cells, CD8 T cells rapidly accumulated 
in the pancreas, which was associated with strong changes in 
the local chemokine milieu (77). This effect was dependent on 
DAP10, but did not require antigen-recognition by T cells (77). 
Surprisingly, accumulation of CD8 T cells in the pancreas of these 
animals did not lead to massive destruction of β-cells or diabetes. 
The molecular mechanism how NKG2D impacts chemotaxis is 
not known, but the involvement of DAP10 again implies a role for 
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PI3 kinase. Many chemokine receptors signal through PI3 kinase, 
either directly, or via G-protein linked signaling (78). Thus, 
NKG2D may indirectly impact the sensitivity of PI3K-linked 
chemokine receptors to change the migration behavior of T cells.
Similar to NK cells, chronic exposure of T cells to NKG2D 
lig ands impairs their responsiveness to stimulation. Characteri-
zation of T cells infiltrating human tumors overexpressing NKG2D 
ligands showed that they downregulate the NKG2D receptor (50). 
As a result, activated T cells become less responsive to NKG2D 
(co-) stimulation (50). Surprisingly, chronic NKG2D ligand 
encounter also results in reduced responsiveness of the TCR. 
Re-stimulation of TILs from a MICA overexpressing human 
melanoma through their TCR showed that they have a reduced 
capacity to produce IFNγ compared to TILs derived from 
melanoma that did not express NKG2D ligands (50). To reca-
pitulate this observation, various experimental models have been 
generated in which mice overexpress NKG2D ligands, either 
ubiquitously or in specific organs. These confirmed that chronic 
NKG2D stimulation impairs responsiveness to tumor antigens 
in particular (57, 79). The molecular mechanism underlying 
impaired responsiveness of the TCR following chronic NKG2D 
stimulation is still a matter of debate. Co-cultivation of human 
peripheral blood CD8 T  cells for several days with fibroblasts 
overexpressing MICA showed that these cells downregulated 
CD3ζ, a key intracellular signaling component of the TCR (58). 
This effect was shown to depend on activation of caspase 3/7, 
which mediated proteolytic degradation of CD3ζ (58). How 
chronic NKG2D drives caspase activation and how this is achieved 
without inducing apoptosis remains unclear. Interestingly, when 
animals which ubiquitously express Rae1ε were infected with 
murine cytomegalovirus, there was no difference observed in 
the number of antigen-specific CD8 T cells, nor in their ability 
to produce cytokines (80). This implies that anergy induced by 
chronic NKG2D stimulation can be overcome in a sufficiently 
inflammatory environment (80).
nKG2D AnD B CeLLS
A surprising role for NKG2D was recently identified in regula-
tion of signaling thresholds in B cells. Mice deficient for NKG2D 
show a specific reduction in the number of B cells in spleen (33). 
In addition, Klrk1−/− mice have a twofold reduction in B1a cells 
in the peritoneal cavities (81). This phenotype partially depended 
on DAP10-mediated signaling, indicating that this may also be 
of relevance for the human situation. NKG2D is not expressed 
on mature B cells or committed B cell precursors. Nevertheless, 
NKG2D is expressed very early during NK  cell development. 
Since B1a cells represent an innate B cell population, it was pos-
tulated that in mice NKG2D is expressed on a common precursor 
for B1a and NK cells (81). Importantly, in a model for B1a cell 
controlled bacterial infection, Klrk1−/− mice behaved similarly to 
B cell-deficient animals (81). Indeed, NKG2D deficiency resulted 
in reduced B cell receptor signaling in B1a cells. Thus, also in the 
B cell lineage, NKG2D appears to have a long-term impact on 
receptor sensitivity.
COnCLUDinG ReMARKS
NKG2D has great potential as a therapeutic target, since it has 
the potency to enhance cytolytic immune responses against 
important diseases, such as cancer. Indeed, chimeric receptors 
using NKG2D signaling domains have successfully been used 
in  vitro to potentiate antitumor T  cells (82, 83). However, the 
complexity of NKG2D biology should be acknowledged before 
the power of this receptor can be harnessed therapeutically. 
NKG2D ligands may be used to communicate cellular stress, 
in which case NKG2D should induce immune cell activation. 
However, when NKG2D ligands are expressed chronically or at 
low intensity, for example during pregnancy in the placenta, they 
communicate a need for reduced receptor responsiveness and 
inhibit immune cell function. Similarly, when NKG2D ligands 
are encountered by NK cell precursors they set the proper band-
width for mature NK cell responsiveness. Thus, NKG2D appears 
to be a sensor of the immunological context in which an immune 
cell operates and it adjusts responsiveness of its other receptors 
accordingly. The signaling pathways via which NKG2D mediates 
its effects on other receptors are only beginning to be unraveled, 
especially in NK cells. Future studies must reveal how we will 
be able to exploit NKG2D-based therapies, without introducing 
unforeseen effects.
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